Company Profile

Luminomics Inc
Profile last edited on: 4/29/16      CAGE: 47HB2      UEI:

Business Identifier: Degenerative zebrafish disease models to enable genetic and pharmacological drug screenings
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1120 15th Street
Augusta, GA 30912
   (706) 721-9344
Location: Single
Congr. District: 12
County: Richmond

Public Profile

Luminomics Inc is a drug discovery firm creating degenerative disease models in Zebrafish to allow identification of the molecular pathways of particular cells and tissue types that stimulate cell-type specific regeneration in vertebrates. The firm has developed an inducible-targeted cellular ablation system, ZAP, which is used to create degenerative disease models in transgenic Zebrafish and allow informed drug screens that dramatically decrease the time and cost of drug discovery. Understanding these genetic pathways, which are employed in the regeneration of discrete cell types, will be directly applicable to the field of stem cell therapeutics. Using the Zebrafish model, the firm focuses on nuerodegenerative diseases such as Parkinson’s and Alzheimer’s disease; however, the platform is applicable to any degenerative disease or condition. These models are then used for genetic and pharmacological screens in an effort to elucidate biochemical pathways, which stimulate cell-type specific regeneration in vertebrate

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2014 1 NIH $225,000
Project Title: Robotic Whole Organism Hts Platform for Drug Discovery and Development
2011 1 NIH $177,074
Project Title: Zinc Finger Nuclease Induced Knockout And Knock-In Models In Zebrafish
2010 1 NIH $217,535
Project Title: Motor Neuron Disease Modeling In Zebrafish
2009 1 NIH $195,511
Project Title: Type I Diabetes Model in Zebrafish
2008 2 NIH $1,478,790
Project Title: Targeted Cellular Ablation in Transgenic Zebrafish

Key People / Management

  Jeffrey S Mumm -- Founder; Chief Executive Officer; President

  Meera T Saxena -- President

  Jonathan Richard Mathias -- Former Senior Research Scientist

Company News

There are no news available.